UnitedHealth Group Incorporated (NYSE:UNH) produced $8.0 billion of second-quarter 2026 operating earnings, with Optum contributing $4.0 billion. Medical inflation and Medicare funding pressure reach both insurance and care delivery, however. The investment question is how much profit survives when treating patients becomes more expensive.
A forward P/E around 17x looks fairly valued for UnitedHealth Group Incorporated if medical margins recover and Optum delivers dependable external profits. Forward P/E values forecast earnings; the approximately 24x trailing reading reflects past-year profits. The recovery outlook includes better pricing and fewer exceptional costs following 2025 restructuring and cyberattack expenses. Management’s separate 2026 non-GAAP adjusted EPS midpoint of $19.75 implies roughly 21% annual growth. That measure excludes intangible amortization, portfolio effects, and restructuring and other specified items.
CVS Health Corporation (NYSE:CVS) is the closest structural peer because it combines insurance, pharmacy benefits, and care delivery. Its retail network adds store expenses and inventory needs. For UnitedHealth Group Incorporated, a richer valuation would require more resilient margins, stronger cash conversion, and manageable financial risk. Optum’s technology earnings can support that case, but shared medical-cost exposure limits the diversification benefit.
Also read: 10 Best Healthcare Stocks to Buy According to Hedge Funds
Different Businesses, Different Sources of Profit
UnitedHealth Group Incorporated combines several payment models. Optum Health earns administrative and treatment fees, but also accepts responsibility for patients’ medical costs in exchange for fixed monthly payments. Higher utilization or provider prices can therefore hurt it alongside UnitedHealthcare. This resembles the distinction between service revenue and accepting underwriting exposure through existing customer relationships.
The shared exposure has already mattered. In 2025, UnitedHealthcare operating earnings fell to $9.4 billion from $15.6 billion, while Optum Health’s non-GAAP adjusted operating earnings fell to $2.3 billion from $7.9 billion, excluding specified portfolio, restructuring, and other effects. Medicare reimbursement pressure and rising treatment costs affected both. Better care coordination can lower total spending, but another subsidiary does not automatically provide a hedge.
Optum Insight offers UnitedHealth Group Incorporated a more distinct earnings source through software, analytics, and administrative services. Customers seeking lower processing costs create demand, although stressed hospitals and insurers can delay purchases. Its second-quarter profit improvement included contract timing. The segment now includes Optum Financial, adding interest income to the earnings mix. As with other software businesses, renewals and cash collection must support recurring revenue.
Optum Rx adds pharmacy services and dispensing economics. It provided a partial offset in 2025, when non-GAAP adjusted operating earnings rose to $6.1 billion from $5.8 billion. UnitedHealth Group Incorporated is moving toward transparent fees and rebate pass-through arrangements. Those contracts can reduce dependence on drug-price-linked compensation, but retaining customers at profitable fees remains essential. Prescription revenue includes drug costs, making revenue scale a poor substitute for operating profit.
Test Diversification at the Group Level
For UnitedHealth Group Incorporated, external demand provides the clearest test. Optum generated $25.4 billion from unaffiliated customers in the quarter, against $39.6 billion of affiliated revenue eliminated on consolidation. External revenue rose just 1.9%, and Optum Insight’s reported external revenue declined 9%. Internal transactions can improve coordination, but ownership must add economic value beyond existing commercial relationships.
The company’s inclusion in 10 Best Bear Market Stocks to Invest In Right Now makes resilience particularly relevant. Genuine diversification should become visible through profitable external contracts and steadier consolidated margins when insurance claims rise.
UnitedHealth Group Incorporated reported $11.1 billion of second-quarter 2026 operating cash flow, helped substantially by government-payment timing. Consolidated cash does not isolate Optum’s contribution. Meanwhile, $860 million of favorable medical reserve development supported earnings, mostly relating to 2026 services. Sustainable recovery requires stronger operating performance beyond payment timing and reserve adjustments.
Conclusion
UnitedHealth Group Incorporated can justify a 17x forward valuation through sustained medical-margin recovery, profitable external growth at Optum Insight and Optum Rx, and disciplined risk contracts at Optum Health. Cash generation must remain strong as payment timing normalizes. Those results would support fair value; segment size alone does not establish a diversification premium.
While we acknowledge the risk and potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UNH and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients? and Roper (ROP): Are Buybacks a Better Use of Cash than More Acquisitions?
This article is originally published at Insider Monkey.
